Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece

[1]  R. Link-Gelles,et al.  Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  Benjamin Bowe,et al.  Acute and postacute sequelae associated with SARS-CoV-2 reinfection , 2022, Nature Medicine.

[3]  COVID-19 update: Novavax vaccine authorized for booster immunization. , 2022, The Medical letter on drugs and therapeutics.

[4]  J. Starrfelt,et al.  Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort , 2022, The Journal of infectious diseases.

[5]  J. Bradley,et al.  Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  William F. Fadel,et al.  Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study , 2022, BMJ.

[7]  D. Hatzigeorgiou,et al.  Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study , 2022, Vaccine.

[8]  Colin Simpson,et al.  Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales , 2022, The Lancet.

[9]  A. Gómez-Carballa,et al.  Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain , 2022, Environmental Research.

[10]  K. Mergenhagen,et al.  Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominance , 2022, American Journal of Infection Control.

[11]  Jue Liu,et al.  Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis , 2022, International journal of environmental research and public health.

[12]  I. Giannopoulou,et al.  Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection , 2022, Vaccine.

[13]  C. Viboud,et al.  Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control , 2022, International Journal of Infectious Diseases.

[14]  R. Bull,et al.  Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission , 2022, Reviews in medical virology.

[15]  M. Penny,et al.  COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups , 2022, Infectious Diseases and Therapy.

[16]  T. Iwashyna,et al.  Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era , 2022, Annals of Internal Medicine.

[17]  E. Lofgren,et al.  How drivers of seasonality in respiratory infections may impact vaccine strategy: a case study in how COVID-19 may help us solve one of influenza's biggest challenges , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Weiss,et al.  Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021 , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Exline,et al.  Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Yuan Shi,et al.  Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review , 2022, Human vaccines & immunotherapeutics.

[21]  P. Fournier,et al.  High rate of reinfection with the SARS-CoV-2 Omicron variant , 2022, Journal of Infection.

[22]  R. Garlantézec,et al.  Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers , 2022, Vaccine.

[23]  J. Starrfelt,et al.  Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021 , 2022, BMC Medicine.

[24]  Gheyath K Nasrallah,et al.  Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.

[25]  D. Fisman,et al.  Relative Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Vaccinated and Unvaccinated Individuals Hospitalized With SARS-CoV-2 , 2022, medRxiv.

[26]  P. Noble,et al.  Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[27]  D. Weiss,et al.  Reduced Odds of SARS-CoV-2 Reinfection after Vaccination among New York City Adults, June-August 2021 , 2021, medRxiv.

[28]  H. Chun,et al.  Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era , 2021, The Lancet Microbe.

[29]  L. Poon,et al.  Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters , 2021, Journal of virology.

[30]  J. Starrfelt,et al.  Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January to September 2021. , 2021, medRxiv.

[31]  V. Raftopoulos,et al.  COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study , 2021, Vaccine.

[32]  Dennis Andersson,et al.  Ensuring trust in COVID-19 data , 2021, Medicine.

[33]  L. Vimercati,et al.  Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study , 2021, Vaccines.

[34]  A. Kotanidou,et al.  Coronavirus disease 2019 pandemic in Greece, February 26 – May 3, 2020: The first wave , 2021, Travel Medicine and Infectious Disease.

[35]  M. Myrskylä,et al.  Years of life lost to COVID-19 in 81 countries , 2021, Scientific Reports.

[36]  A. Deane,et al.  Global impact of COVID-19 infection requiring admission to the intensive care unit: a systematic review and meta-analysis , 2020, Chest.

[37]  A. Deane,et al.  Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU , 2020, Chest.

[38]  G. Poland,et al.  Influenza immunization and COVID-19 , 2020, Vaccine.

[39]  M E Halloran,et al.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines. , 1997, American journal of epidemiology.